206 related articles for article (PubMed ID: 26123354)
1. Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.
Thompson EA; Liang F; Lindgren G; Sandgren KJ; Quinn KM; Darrah PA; Koup RA; Seder RA; Kedl RM; Loré K
J Immunol; 2015 Aug; 195(3):1015-24. PubMed ID: 26123354
[TBL] [Abstract][Full Text] [Related]
2. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
4. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
5. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
[TBL] [Abstract][Full Text] [Related]
6. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
7. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.
Trumpfheller C; Longhi MP; Caskey M; Idoyaga J; Bozzacco L; Keler T; Schlesinger SJ; Steinman RM
J Intern Med; 2012 Feb; 271(2):183-92. PubMed ID: 22126373
[TBL] [Abstract][Full Text] [Related]
9. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR
J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
[TBL] [Abstract][Full Text] [Related]
11. Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity.
Pérez-Girón JV; Belicha-Villanueva A; Hassan E; Gómez-Medina S; Cruz JL; Lüdtke A; Ruibal P; Albrecht RA; García-Sastre A; Muñoz-Fontela C
J Immunol; 2014 Aug; 193(3):1324-32. PubMed ID: 24958904
[TBL] [Abstract][Full Text] [Related]
12. A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.
Ruane D; Do Y; Brane L; Garg A; Bozzacco L; Kraus T; Caskey M; Salazar A; Trumpheller C; Mehandru S
Mucosal Immunol; 2016 Sep; 9(5):1340-52. PubMed ID: 26732678
[TBL] [Abstract][Full Text] [Related]
13. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
[TBL] [Abstract][Full Text] [Related]
14. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.
Flynn BJ; Kastenmüller K; Wille-Reece U; Tomaras GD; Alam M; Lindsay RW; Salazar AM; Perdiguero B; Gomez CE; Wagner R; Esteban M; Park CG; Trumpfheller C; Keler T; Pantaleo G; Steinman RM; Seder R
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7131-6. PubMed ID: 21467219
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
[TBL] [Abstract][Full Text] [Related]
16. Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.
Sultan H; Wu J; Kumai T; Salazar AM; Celis E
Cancer Immunol Immunother; 2018 Jul; 67(7):1091-1103. PubMed ID: 29696308
[TBL] [Abstract][Full Text] [Related]
17. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes.
Rolph MS; Kaufmann SH
J Immunol; 2001 Apr; 166(8):5115-21. PubMed ID: 11290793
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
[TBL] [Abstract][Full Text] [Related]
19. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates.
Park H; Adamson L; Ha T; Mullen K; Hagen SI; Nogueron A; Sylwester AW; Axthelm MK; Legasse A; Piatak M; Lifson JD; McElrath JM; Picker LJ; Seder RA
J Immunol; 2013 Apr; 190(8):4103-15. PubMed ID: 23509365
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
